Intravenous immune globulin has been used in the treatment of primary and secondary
antibody deficiencies for more than 25 years. It is a safe preparation with no long-term side …

Pulmonary alveolar proteinosis is a rare clinical syndrome that was first described in 1958.
Subsequently, over 240 case reports and small series have described at least 410 cases in …

US8034337B2 - Interleukin-1α antibodies - Google Patents US8034337B2 - Interleukin-1α
antibodies - Google Patents Interleukin-1α antibodies Download PDF Info Publication number …

Idiopathic pulmonary alveolar proteinosis (I-PAP) is a rare disease of unknown etiology in
which the alveoli fill with lipoproteinaceous material. We report here that I-PAP is an …

Although definitive proof of a causal role of infection contributing to atherogenesis is lacking,
multiple investigations have demonstrated that infectious agents evoke cellular and …

Cryptococcosis is caused by either Cryptococcus neoformans or C. gattii. While cryptococcal
meningoencephalitis is caused mostly by C. neoformans in immunocompromised patients …

Autoantibodies to multiple cytokines have been identified and some, including antibodies
against granulocyte-macrophage colony-stimulating factor (GM-CSF), have been associated …

Normal immunoglobulin G for therapeutic use (intravenous immunoglobulin [IVIg]) is used in
an increasing number of immune-mediated conditions, including acute and …

Pulmonary alveolar proteinosis (PAP) comprises a heterogenous group of diseases
characterized by abnormal surfactant accumulation resulting in respiratory insufficiency, and …

Initially used as a replacement therapy for immunodeficiency diseases, intravenous
immunoglobulin (IVIg) is now widely used for a number of autoimmune and inflammatory …